Terms: = Bone cancer AND KMT2A, TRX1, 4297, MLL, ENSG00000118058, MLL/GAS7, HTRX1, HRX, ALL-1, MLL1A, CXXC7 AND Treatment
123 results:
1. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
Conter V; Valsecchi MG; Cario G; Zimmermann M; Attarbaschi A; Stary J; Niggli F; Dalla Pozza L; Elitzur S; Silvestri D; Locatelli F; Möricke A; Engstler G; Smisek P; Bodmer N; Barbaric D; Izraeli S; Rizzari C; Boos J; Buldini B; Zucchetti M; von Stackelberg A; Matteo C; Lehrnbecher T; Lanvers-Kaminsky C; Cazzaniga G; Gruhn B; Biondi A; Schrappe M
J Clin Oncol; 2024 Mar; 42(8):915-926. PubMed ID: 38096462
[TBL] [Abstract] [Full Text] [Related]
2. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia.
Li Z; Liu X; Wang L; Zhao H; Wang S; Yu G; Wu D; Chu J; Han J
Front Immunol; 2023; 14():1281687. PubMed ID: 38022588
[TBL] [Abstract] [Full Text] [Related]
3. Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia.
McNerney KO; Moskop A; Winestone LE; Baggott C; Talano JA; Schiff D; Rossoff J; Modi A; Verneris MR; Laetsch TW; Schultz L
Transplant Cell Ther; 2024 Jan; 30(1):75.e1-75.e11. PubMed ID: 37816472
[TBL] [Abstract] [Full Text] [Related]
4. Distinct and targetable role of calcium-sensing receptor in leukaemia.
Pereira RS; Kumar R; Cais A; Paulini L; Kahler A; Bravo J; Minciacchi VR; Krack T; Kowarz E; Zanetti C; Godavarthy PS; Hoeller F; Llavona P; Stark T; Tascher G; Nowak D; Meduri E; Huntly BJP; Münch C; Pampaloni F; Marschalek R; Krause DS
Nat Commun; 2023 Oct; 14(1):6242. PubMed ID: 37802982
[TBL] [Abstract] [Full Text] [Related]
5. Mechanisms of Secondary Leukemia Development Caused by treatment with DNA Topoisomerase Inhibitors.
Lomov NA; Viushkov VS; Rubtsov MA
Biochemistry (Mosc); 2023 Jul; 88(7):892-911. PubMed ID: 37751862
[TBL] [Abstract] [Full Text] [Related]
6. Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for treatment of AML.
Kelvin JM; Jain J; Thapa A; Qui M; Birnbaum LA; Moore SG; Zecca H; Summers RJ; Switchenko JM; Costanza E; Uricoli B; Wang X; Jui NT; Fu H; Du Y; DeRyckere D; Graham DK; Dreaden EC
Pharm Res; 2023 Sep; 40(9):2133-2146. PubMed ID: 37704893
[TBL] [Abstract] [Full Text] [Related]
7. Clinical and Molecular Characteristics of Patients with Mixed Phenotype Acute Leukemia.
Kandeel EZ; Hassan NM; El Ashry MS
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1217-1223. PubMed ID: 37116143
[TBL] [Abstract] [Full Text] [Related]
8. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01.
Hosono N; Chi S; Yamauchi T; Fukushima K; Shibayama H; Katagiri S; Gotoh A; Eguchi M; Morishita T; Ogasawara R; Kondo T; Yanada M; Yamamoto K; Kobayashi T; Kuroda J; Usuki K; Utsu Y; Yoshimitsu M; Ishitsuka K; Ono T; Takahashi N; Iyama S; Kojima K; Nakamura Y; Fukuhara S; Izutsu K; Abutani H; Yamauchi N; Yuda J; Minami Y;
Cancer Sci; 2023 May; 114(5):2098-2108. PubMed ID: 36793248
[TBL] [Abstract] [Full Text] [Related]
9. A secondary CD34+ acute lymphoblastic leukemia unmasked and mobilized by G-CSF in an autologous stem cell donor with testicular cancer.
Cooling L; Kelley J; Sexton E; Anand S; Hoffmann S
Transfusion; 2023 Apr; 63(4):684-689. PubMed ID: 36762622
[TBL] [Abstract] [Full Text] [Related]
10. Preclinical efficacy of azacitidine and venetoclax for infant kmt2a-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS
Leukemia; 2023 Jan; 37(1):61-71. PubMed ID: 36380143
[TBL] [Abstract] [Full Text] [Related]
11. Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.
Nedumannil R; Ritchie D; Bajel A; Ng AP; Harrison SJ; Westerman D
Eur J Haematol; 2023 Feb; 110(2):168-176. PubMed ID: 36321745
[TBL] [Abstract] [Full Text] [Related]
12. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
[TBL] [Abstract] [Full Text] [Related]
13. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with kmt2a rearrangements.
Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
[TBL] [Abstract] [Full Text] [Related]
14. NADPH metabolism determines the leukemogenic capacity and drug resistance of AML cells.
Chen C; Lai X; Zhang Y; Xie L; Yu Z; Dan S; Jiang Y; Chen W; Liu L; Yang Y; Huang D; Zhao Y; Zheng J
Cell Rep; 2022 Apr; 39(1):110607. PubMed ID: 35385727
[TBL] [Abstract] [Full Text] [Related]
15. Minimal residual disease and outcome characteristics in infant kmt2a-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
Stutterheim J; de Lorenzo P; van der Sluis IM; Alten J; Ancliffe P; Attarbaschi A; Aversa L; Boer JM; Biondi A; Brethon B; Diaz P; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Leung AW; Locatelli F; Silverman L; Stary J; Szczepanski T; van der Velden VHJ; Vora A; Zuna J; Schrappe M; Valsecchi MG; Pieters R
Eur J Cancer; 2022 Jan; 160():72-79. PubMed ID: 34785111
[TBL] [Abstract] [Full Text] [Related]
16. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and kmt2a-rearranged AML.
Menghrajani K; Gomez-Arteaga A; Madero-Marroquin R; Zhang MJ; Bo-Subait K; Sanchez J; Wang HL; Aljurf M; Assal A; Bacher VU; Badawy SM; Bejanyan N; Bhatt VR; Bredeson C; Byrne M; Castillo P; Cerny J; Chhabra S; Ciurea SO; DeFilipp Z; Farhadfar N; Gadalla S; Gale RP; Ganguly S; Gowda L; Grunwald MR; Hashmi S; Hildebrandt G; Kanakry CG; Kansagra A; Khimani F; Krem M; Lazarus H; Liu H; Martino R; Michelis FV; Nathan S; Nishihori T; Olsson R; Reshef R; Rizzieri D; Rowe JM; Savani BN; Seo S; Sharma A; Solh M; Ustun C; Verdonck LF; Hourigan C; Sandmaier B; Litzow M; Kebriaei P; Weisdorf D; Zhang Y; Tallman MS; Saber W
Blood Adv; 2022 Jan; 6(3):828-847. PubMed ID: 34551064
[TBL] [Abstract] [Full Text] [Related]
17. The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.
Khateb A; Deshpande A; Feng Y; Finlay D; Lee JS; Lazar I; Fabre B; Li Y; Fujita Y; Zhang T; Yin J; Pass I; Livneh I; Jeremias I; Burian C; Mason JR; Almog R; Horesh N; Ofran Y; Brown K; Vuori K; Jackson M; Ruppin E; Deshpande AJ; Ronai ZA
Nat Commun; 2021 Sep; 12(1):5397. PubMed ID: 34518534
[TBL] [Abstract] [Full Text] [Related]
18. treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML.
Zhang B; Nguyen LXT; Zhao D; Frankhouser DE; Wang H; Hoang DH; Qiao J; Abundis C; Brehove M; Su YL; Feng Y; Stein A; Ghoda L; Dorrance A; Perrotti D; Chen Z; Han A; Pichiorri F; Jin J; Jovanovic-Talisman T; Caligiuri MA; Kuo CJ; Yoshimura A; Li L; Rockne RC; Kortylewski M; Zheng Y; Carlesso N; Kuo YH; Marcucci G
J Hematol Oncol; 2021 Aug; 14(1):122. PubMed ID: 34372909
[TBL] [Abstract] [Full Text] [Related]
19. Therapy-related acute myeloid leukemia with kmt2a-SNX9 gene fusion associated with a hyperdiploid karyotype after hemophagocytic lymphohistiocytosis.
Sardou-Cezar I; Lopes BA; Andrade FG; Fonseca TCC; Fernandez TS; Larghero P; de Souza RQ; Loth G; Ribeiro LL; Bonfim C; Morgado ES; Marschalek R; Meyer C; Pombo-de-Oliveira MS
Cancer Genet; 2021 Aug; 256-257():86-90. PubMed ID: 34034210
[TBL] [Abstract] [Full Text] [Related]
20. Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Smith SM; Sabnis HS; Lewis RW; Effinger KE; Bergsagel J; Patterson B; Mertens A; Sakamoto KM; Schapira L; Castellino SM
BMC Cancer; 2021 Apr; 21(1):474. PubMed ID: 33926411
[TBL] [Abstract] [Full Text] [Related]
[Next]
